Pulmonary Disorders and TPE, Therapeutic plasma exchange, Clinical Pathology - Full Vignette with Ex

Описание: A 41-year-old woman presents 10 months after bilateral lung transplantation with sudden onset dyspnea, pleuritic chest pain, and a high fever following recent travel to Southeast Asia. Her oxygen needs are increasing and imaging reveals new bilateral ground-glass opacities. How should clinicians approach this complex scenario? What findings are most important in guiding urgent management decisions for transplant recipients presenting with acute respiratory symptoms?

VIDEO INFO
Category: Pulmonary Disorders and TPE, Therapeutic plasma exchange, Clinical Pathology
Difficulty: Expert - Expert level - For those seeking deep understanding
Question Type: Clinical Trials
Case Type: Emergency - Emergency scenario requiring urgent decision-making

Explore more ways to learn on this and other topics by going to https://endlessmedical.academy/auth?h...

QUESTION
A 41-year-old woman, 10 months after bilateral lung transplantation for end-stage bronchiolitis obliterans, presents to the ED with abrupt dyspnea, pleuritic chest pain, and fever to 41.4 degreesC. She works in food service, is abstinent from prior methamphetamine use, and recently returned from a 9-day trip to Southeast Asia. She reports medication adherence. Allergies are none known....

OPTIONS
A. Begin therapeutic plasma exchange via citrate anticoagulation daily or on alternate days for 5-7 sessions (1.0-1.5 plasma volumes) with high-dose IV methylprednisolone in the ICU; administer IVIG 2 g/kg total (e.g., 1-2 days) at the end of the exchange series or give 100 mg/kg after each session;...
B. Give rituximab 375 mg/m^2 immediately in the ED, start plasma exchange within 2 hours, and infuse a cumulative IVIG dose of 10 g/kg divided across exchanges so that circulating immunoglobulin levels remain high during antibody clearance.
C. Use immunoadsorption alone for three sessions without adjunctive immunomodulation, because it preserves coagulation factors and has randomized data proving superiority over plasma exchange for acute lung antibody-mediated rejection.
D. Avoid extracorporeal therapies and initiate tocilizumab monotherapy as first-line treatment based on controlled trials showing improved survival compared with exchange-based regimens for pulmonary antibody-mediated rejection.

CORRECT ANSWER
A. Begin therapeutic plasma exchange via citrate anticoagulation daily or on alternate days for 5-7 sessions (1.0-1.5 plasma volumes) with high-dose IV methylprednisolone in the ICU; administer IVIG 2 g/kg total (e.g., 1-2 days) at the end of the exchange series or give 100 mg/kg after each session; schedule rituximab 375 mg/m^2 after the final exchange to avoid drug removal; consider complement or IL-6 pathway blockade only if refractory.

EXPLANATION
In lung transplant antibody-mediated rejection with capillaritis, C4d positivity, rising class II donor-specific antibodies with complement binding, and clinical allograft dysfunction, emergent rescue typically employs multi-session TPE to rapidly reduce circulating pathogenic antibodies, paired with high-dose methylprednisolone. Because TPE removes infused immunoglobulins and B-cell-directed agents, IVIG should be timed to remain in the circulation-either as 2 g/kg total at the series end or fractionated (for example, 100 mg/kg) after each session-and rituximab should be administered after the final exchange to avoid removal. Daily or alternate-day 1.0-1.5 PV exchanges over 5-7 sessions are standard practice patterns in tertiary centers, with citrate anticoagulation and calcium management....


Further reading:

Links to sources are provided for optional further reading only. The questions and explanations are independently authored and do not reproduce or adapt any specific third-party text or content.

---------------------------------------------------

Our cases and questions come from the https://EndlessMedical.Academy quiz engine - multi-model platform. Each question and explanation is forged by consensus between multiple top AI models (i.e. Open AI GPT, Claude, Grok, etc.), with automated web searches for the latest research and verified references. Calculations (e.g. eGFR, dosages) are checked via code execution to eliminate errors, and all references are reviewed by several AIs to minimize hallucinations.

Important note: This material is entirely AI-generated and has not been verified by human experts; despite stringent consensus checks, perfect accuracy cannot be guaranteed. Exercise caution - always corroborate the content with trusted references or qualified professionals, and never apply information from this content to patient care or clinical decisions without independent verification.

Clinicians already rely on AI and online tools - myself included - so treat this content as an additional focused aid, not a replacement for proper medical education. Visit https://endlessmedical.academy for more AI-supported resources and cases.

This material can not be treated as medical advic